Statistical issues in the analysis of adverse events in time‐to‐event data

The aim of this work is to shed some light on common issues in the statistical analysis of adverse events (AEs) in clinical trials, when the main outcome is a time-to-event endpoint. To begin, we show that AEs are always subject to competing risks. That is, the occurrence of a certain AE may be precluded by occurrence of the main time-to-event outcome or by occurrence of another (fatal) AE. This has raised concerns on 'informative' censoring. We show that, in general, neither simple proportions nor Kaplan-Meier estimates of AE occurrence should be used, but common survival techniques for hazards that censor the competing event are still valid, but incomplete analyses. They must be complemented by an analogous analysis of the competing event for inference on the cumulative AE probability. The commonly used incidence rate (or incidence density) is a valid estimator of the AE hazard assuming it to be time constant. An estimator of the cumulative AE probability can be derived if the incidence rate of AE is combined with an estimator of the competing hazard. We discuss less restrictive analyses using non-parametric and semi-parametric approaches. We first consider time-to-first-AE analyses and then briefly discuss how they can be extended to the analysis of recurrent AEs. We will give a practical presentation with illustration of the methods by a simple example. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  D. Machin,et al.  Analysis and design of randomised clinical trials involving competing risks endpoints , 2011, Trials.

[2]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[3]  M. Pagano,et al.  Survival analysis. , 1996, Nutrition.

[4]  G Rauch,et al.  Planning and evaluating clinical trials with composite time‐to‐first‐event endpoints in a competing risk framework , 2013, Statistics in medicine.

[5]  Martin Schumacher,et al.  Incidence densities in a competing events analysis. , 2010, American journal of epidemiology.

[6]  John E. Gait,et al.  Evaluation of Safety Data from Controlled Clinical Trials: The Clinical Principles Explained , 2000 .

[7]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[8]  J. Windeler,et al.  Events per person year—a dubious concept , 1995, BMJ.

[9]  Z. Bankowski,et al.  Council for International Organizations of Medical Sciences , 1991 .

[10]  Toshiro Tango,et al.  Non‐parametric inference of adverse events under informative censoring , 2006, Statistics in medicine.

[11]  Martin Schumacher,et al.  Incidence in ICU populations: how to measure and report it? , 2014, Intensive Care Medicine.

[12]  R. O’Neill Statistical Analyses of Adverse Event Data from Clinical Trials , 1987, Drug information journal.

[13]  H. Kraemer Events per person‐time (incidence rate): A misleading statistic? , 2009, Statistics in medicine.

[14]  Jixian Wang,et al.  Nonparametric estimation for cumulative duration of adverse events. , 2012, Biometrical journal. Biometrische Zeitschrift.

[15]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[16]  Mark J. van der Laan,et al.  Application of Time-to-Event Methods in the Assessment of Safety in Clinical Trials , 2009 .

[17]  Richard J. Cook,et al.  The Statistical Analysis of Recurrent Events , 2007 .

[18]  Liang Fang,et al.  Analysis of safety data in clinical trials using a recurrent event approach. , 2014, Pharmaceutical statistics.

[19]  J. Fine,et al.  A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. , 2013, Journal of clinical epidemiology.

[20]  Niels Keiding,et al.  Interpretability and importance of functionals in competing risks and multistate models , 2012, Statistics in medicine.

[21]  J. Vandenbroucke Continuing controversies over "risks and rates" – more than a century after William Farr's "On prognosis" , 2003, Sozial- und Präventivmedizin/Social and Preventive Medicine.

[22]  Martin Schumacher,et al.  Competing Risks and Multistate Models , 2012, Clinical Cancer Research.

[23]  Jan Beyersmann,et al.  Classical Regression Models for Competing Risks , 2013 .

[24]  Martin Schumacher,et al.  Competing Risks and Multistate Models with R , 2011 .